Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03694834
Title Window of Opportunity Study of Pembrolizumab in Early Stage, High Grade Obesity-driven Endometrial Cancer
Recruitment Suspended
Gender female
Phase Phase I
Variant Requirements No
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

endometrial adenocarcinoma

endometrial serous adenocarcinoma

endometrial clear cell adenocarcinoma

Therapies

Pembrolizumab

Carboplatin + Paclitaxel + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.